Ab­b­Vie puts up $40M to li­cense a treat­ment from HotSpot Ther­a­peu­tics

HotSpot Ther­a­peu­tics has man­aged to gain some steam fi­nan­cial­ly in the past few years, as the com­pa­ny wran­gled sev­er­al mul­ti-mil­lion dol­lar rais­es. But its lat­est …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER